Healthcare / BiotechnologyOslo
$3.41
+0.21 (+6.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-65.1M · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$92M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.6%
↓Gross Margin
27.5%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
—
FCF margin
-113.2%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.1M · net income $-41.0M · FCF $-45.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.1M | $40.1M | $43.5M | $33.8M | $34.3M |
| Net Income | $-41.0M | $-41.0M | $-47.9M | $-45.5M | $-34.0M |
| EBITDA | $-26.8M | $-26.8M | $-39.6M | $-39.1M | $-30.3M |
| EPS | -1.52 | -1.52 | -1.89 | -1.79 | -1.39 |
| Gross Margin | 27.5% | 27.5% | 27.3% | 29.0% | 34.0% |
| Operating Margin | -83.4% | -83.4% | -109.9% | -144.0% | -109.1% |
| Net Margin | -102.3% | -102.3% | -110.2% | -134.9% | -99.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.15 | 0.02 | 0.00 |
| Current Ratio | 0.59 | 0.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-45.4M | $-45.4M | $-96.2M | $-65.1M | $-84.0M |
| Returns | |||||
| ROE | -23.6% | -23.6% | -22.7% | -17.6% | -11.8% |
| Valuation | |||||
| P/B | 0.53 | 0.53 | 0.23 | 1.05 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | -7.8% | -7.8% | 28.8% | -1.5% | — |
| EPS Growth | 19.6% | 19.6% | -5.6% | -28.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.89 → -1.52
Residual
+3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.